狂犬病ワクチン市場レポート：動向、予測、競合分析 (2031年まで)

世界の狂犬病ワクチン市場の将来は、病院、在宅医療、専門クリニックの各市場における機会によって有望視されています。世界の狂犬病ワクチン市場は、2025年から2031年までのCAGRが4.4%で、2031年までに推定13億米ドルに達すると予想されています。この市場の主な促進要因は、狂犬病のリスクに対する意識の高まりと、キツネやアライグマなどの野生動物の狂犬病対策への取り組みの拡大です。

• 製品種類別では、実現可能性、安全性、免疫原性の高さなど多くの利点があり、曝露前・曝露後予防に使用されることから、予測期間中に最も高い成長が見込まれるのはベロ細胞であるとLucintelは予測しています。
• 最終用途別では、病院での狂犬病予防接種処方件数が増加していることから、予測期間中に最も高い成長が見込まれます。
• 地域別では、北米はその強固な医療インフラと製薬会社の増加により、引き続き最大の地域となります。

狂犬病ワクチン市場の戦略的成長機会

狂犬病ワクチン市場は、主要な用途においていくつかの戦略的成長機会を提供しています。これらには、ワクチンの技術的進歩、認知度の向上、公衆衛生イニシアチブの増加などが含まれます。

• ヒトへのワクチン接種プログラム：特にリスクの高い地域におけるヒトへの狂犬病ワクチン接種プログラムの開発は、大きな成長機会となります。サービスへのアクセス向上と集中的なキャンペーンにより、疾病の制御と予防が促進されます。
• 動物ワクチン接種への取り組み：狂犬病の蔓延を防ぐため、動物へのワクチン接種の必要性が高まっています。動物へのワクチン接種に力を入れることで、狂犬病の発生を抑制し、人への感染を減少させることができます。
• 混合ワクチンの開発：複数の病気を予防できる混合ワクチンの提供も成長機会のひとつです。このようなワクチンの接種スケジュールはより簡単なものとなり、患者にとって遵守しやすいものとなります。
• 革新的な送達方法：もう一つの可能性は、マイクロニードルパッチや経口ワクチンなど、革新的なワクチン送達方法の調査です。これらは、ワクチンの受容率を高め、服用をより便利にするのに役立ちます。
• 市場アクセスの拡大：流通とロジスティクスの改善により、新興市場でのアクセスが向上し、市場拡大の機会がもたらされます。このような取り組みにより、これまで不足していたワクチンが、十分なサービスを受けていない分野でも広く利用できるようになり、市場へのさらなる浸透が促進されます。

このような成長機会は、技術革新を促進すると同時に、アクセスを拡大し、疾病対策を改善することによって、狂犬病ワクチン市場を形成しています。世界の狂犬病問題に効果的に対処し、公衆衛生への介入を強化するためには、これらの課題に取り組む必要があります。

狂犬病ワクチン市場促進要因・課題

狂犬病ワクチン市場は、技術進歩、経済要因、規制上の考慮事項など、さまざまな市場促進要因・課題の影響を受けています。これらの要素を理解することは、市場開拓にとって極めて重要です。

狂犬病ワクチン市場を牽引する要因は以下の通りです：

• 技術の進歩：ワクチン技術の市場成長は、革新的な組み換えワクチンや混合ワクチンに起因しています。これらの変化により、製品の安全性と有効性が向上し、疾病をより適切にコントロールできるようになりました。
• 認識と教育の向上：狂犬病とその予防接種に関する意識の向上により、ワクチンの需要が増加しています。そのため、ワクチン接種率を高めるためには、健康キャンペーンや教育活動が必要です。
• 政府の取り組み：市場の拡大は、狂犬病予防接種プログラムに対する政府の支援政策や資金援助によって促進されてきました。予防接種率を拡大し、アウトブレイクを抑制する上で政府が果たす役割は、いくら強調してもしすぎることはありません。
• ワクチンへのアクセスの拡大：流通システムとロジスティクスの改善により、十分なサービスを受けていない地域でもアクセスしやすくなり、以前よりも多くのワクチンを受け取ることができるようになりました。コールドチェーン管理の改善は、対象を絞ったプログラムと相まって、ワクチンの幅広い入手を容易にしています。
• 研究開発：新しい送達システムなど、ワクチン技術の革新が続いています。こうした研究開発なくして、より効果的で便利なワクチン接種方法を開発する機会はありません。

狂犬病ワクチン市場における課題は以下の通り：

• 規制上のハードル：製品開発中やワクチンの承認を得ようとする際に、さまざまな国際基準に準拠することは、複雑な規制要件のために困難な場合があります。国際的に満たさなければならない基準が複数あるため、ワクチンの承認手続きを進めることが難しく、製品開発や市場開拓を複雑にしています。
• 高コスト：先進的ワクチンの開発・製造コストは非常に高く、特にアフリカのような狂犬病の蔓延が著しい低資源国では、価格設定や購入しやすい価格に影響を及ぼす可能性があります。この種のワクチンの製造には多額の資金が必要であり、高いコストがかかります。
• ワクチン接種のためらい：ワクチン接種率の向上は、ワクチン接種へのためらいや誤った情報への対処にかかっています。ワクチン受容の障壁を取り除くには、一般市民への教育と関与が必要です。

これらの市場促進要因・課題は、技術革新、アクセス、公衆衛生への取り組みに影響を与え、狂犬病ワクチン市場に大きな影響を与えます。これらの要素に取り組むことで、狂犬病対策を改善し、ワクチン接種率を拡大することができます。

目次

第1章 エグゼクティブサマリー

第2章 世界の狂犬病ワクチン市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 市場動向と予測分析 (2019年～2031年)

• マクロ経済動向 (2019～2024年) と予測 (2025～2031年)
• 世界の狂犬病ワクチン市場の動向 (2019～2024年) と予測 (2025～2031年)
• 世界の狂犬病ワクチン市場：製品種類別
  • BHK (ベビーハムスター腎臓)
  • 狂犬病向けPCEC (精製ニワトリ胚細胞) ワクチン
  • 狂犬病向けベロ細胞ワクチン
  • その他
• 世界の狂犬病ワクチン市場：ワクチン接種の種類別
  • 曝露前ワクチン接種（PEV）
  • 曝露後予防（PEP）
• 世界の狂犬病ワクチン市場：用途別
  • 動物
  • 人間
• 世界の狂犬病ワクチン市場：最終用途別
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第4章 地域別の市場動向と予測分析 (2019年～2031年)

• 世界の狂犬病ワクチン市場：地域別
• 北米の狂犬病ワクチン市場
• 欧州の狂犬病ワクチン市場
• アジア太平洋の狂犬病ワクチン市場
• その他地域の狂犬病ワクチン市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の狂犬病ワクチン市場の成長機会：製品の種類別
  • 世界の狂犬病ワクチン市場の成長機会：ワクチン接種の種類別
  • 世界の狂犬病ワクチン市場の成長機会：用途別
  • 世界の狂犬病ワクチン市場の成長機会：最終用途別
  • 世界の狂犬病ワクチン市場の成長機会：地域別
• 世界の狂犬病ワクチン市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の狂犬病ワクチン市場の生産能力拡大
  • 世界の狂犬病ワクチン市場における企業合併・買収 (M&A)、合弁事業
  • 認証とライセンシング

第7章 主要企業のプロファイル

• Serum Institute of India
• Novartis
• Cadila Pharmaceuticals
• Merck
• Sanofi
• ADS Diagnostic
• GSK

The future of the global rabies vaccine market looks promising with opportunities in the hospital, home care, and specialty clinic markets. The global rabies vaccine market is expected to reach an estimated $1.3 billion by 2031 with a CAGR of 4.4% from 2025 to 2031. The major drivers for this market are the rising awareness of the risks of rabies and growing efforts to control rabies in wildlife populations, such as foxes and raccoons.

• Lucintel forecasts that, within the product type category, vero cell is expected to witness the highest growth over the forecast period due to its numerous benefits, such as its feasibility, safety, and high immunogenicity, and its use for pre-and post-exposure prophylaxis.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period due to the increasing number of rabies vaccination prescriptions issued within these facilities.
• In terms of regions, North America will remain the largest region due to its robust healthcare infrastructure and the growing number of pharmaceutical companies in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Rabies Vaccine Market

Numerous technological advancements, changing healthcare needs, and an increasing global focus on disease prevention are driving the current trends in the rabies vaccine market.

• Enhanced Vaccine Technologies: These include recombinant and DNA vaccines that have improved their effectiveness and safety profiles for rabies vaccination. They offer more efficacious and less mild alternatives to the existing rabies vaccines.
• Combination Vaccines: More people today prefer combination vaccines that protect against multiple diseases, including rabies. This simplifies vaccination schedules and promotes compliance among patients.
• Expanded Access and Distribution: Currently, there is a growing focus on expanding access to low-cost rabies vaccines in low-resource settings. Better distribution networks and public health awareness campaigns are leading to higher immunization coverage rates, thus helping to control these diseases.
• Increased Focus on Animal Vaccination: In high rabies incidence areas, animal vaccination is now more important than ever before. Failure to vaccinate animals implies that humans can be affected as a consequence of an outbreak of this disease.
• Novel Delivery Methods: Ongoing studies are exploring novel methods of administering vaccines, such as microneedle patches and oral vaccines, to make vaccination more effective, especially for humans and animals.

These trends improve vaccine technology and expand access while enhancing other disease prevention strategies, thereby reshaping the rabies vaccine market, which contributes significantly to better overall worldwide control measures against rabies.

Recent Developments in the Rabies Vaccine Market

The rabies vaccine market is experiencing considerable progress as a result of technological innovation, regulatory amendments, and increased concern for disease prevention. These developments are shaping the future of rabies vaccination.

• Recombinant Vaccines: The introduction of recombinant rabies vaccines has made them safer and more effective. They involve genetic engineering, leading to newer, better immunizations with fewer side effects.
• Expanded Vaccination Campaigns: Global efforts to expand rabies vaccination campaigns are leading to greater coverage in high-risk areas. These interventions encompass human and animal vaccination schemes designed to contain outbreaks.
• Combination Vaccines: The development of combination vaccines that prevent multiple diseases is gaining momentum. Such vaccines make it easier to immunize many people at once and thus contribute positively to public health outcomes.
• Improved Distribution Networks: Advances in distribution and logistics have improved accessibility to rabies vaccines in remote and underserved areas. This includes better cold chain management and targeted vaccination programs.
• Innovative Research: Continued research on alternative vaccine technologies, such as oral vaccines and microneedle vaccinations, is advancing the field. These innovations aim to enhance vaccine delivery methods and improve patient compliance, among other goals.

By enhancing vaccine safety, increasing availability, and driving innovation, these developments significantly impact the rabies vaccine market. They are important in improving worldwide efforts to control this disease by preventing its spread through various channels.

Strategic Growth Opportunities for Rabies Vaccine Market

The rabies vaccine market offers several strategic growth opportunities in major applications. These include technological advancements in vaccines, improved awareness, and increased public health initiatives.

• Human Vaccination Programs: Developing human rabies vaccination programs, particularly in high-risk regions, represents a huge opportunity for growth. The control and prevention of disease can be facilitated through better access to services and focused campaigns.
• Animal Vaccination Initiatives: There is an increasing need to vaccinate animals to prevent the spread of rabies. Concentrating more on animal vaccinations will help control outbreaks and decrease human cases.
• Combination Vaccine Development: Offering combination vaccines that can prevent multiple illnesses is another area of opportunity for growth. Immunization schedules for these vaccines will be easier, making it easier for patients to comply with them.
• Innovative Delivery Methods: Another possibility is research into innovative vaccine delivery methods, such as microneedle patches and oral vaccines, which have growth potential. They can help enhance vaccine acceptance rates and make the doses more convenient.
• Expanded Market Access: Improvement in distribution and logistics, leading to better accessibility in emerging markets, presents expansion opportunities. Such efforts would result in wider availability of previously scarce vaccines across underserved sectors, thereby driving further market penetration.

These growth opportunities are shaping the rabies vaccine market by fostering innovation while also expanding access and improving disease control measures. They must be addressed if global rabies issues are to be dealt with effectively, thus enhancing public health interventions.

Rabies Vaccine Market Driver and Challenges

The rabies vaccine market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory considerations. Understanding these elements is crucial for market development.

The factors responsible for driving the rabies vaccine market include:

• Technological Advancements: Market growth in vaccine technology can be attributed to innovative recombinant and combination vaccines. These changes have made it possible to control diseases better by increasing product safety and effectiveness.
• Increased Awareness and Education: Demand for vaccines is increasing due to improved awareness about rabies and its prevention through vaccination. Therefore, health campaigns and educational efforts are necessary for enhancing vaccination rates.
• Government Initiatives: Market expansion has been fueled by supportive government policies and funding for rabies vaccination programs. The role played by governments in scaling up immunization coverage and controlling outbreaks cannot be overemphasized.
• Expanded Access to Vaccines: Better distribution systems and logistics are making underserved areas more accessible, enabling them to receive more vaccines than before. Improved cold chain management, coupled with targeted programs, facilitates wider availability of vaccines.
• Research and Development: There is ongoing innovation in vaccine technologies, such as new delivery systems. Without this research, there would be no opportunity to develop more effective or convenient ways of vaccinating people.

Challenges in the rabies vaccine market include:

• Regulatory Hurdles: Complying with different international standards during product development or when trying to obtain approval for a vaccine can be difficult due to complex regulatory requirements. This makes navigating procedures for vaccine approval challenging and complicates product development and market entry due to the multiple standards that must be met internationally.
• High Costs: The developing and manufacturing costs associated with advanced vaccines can be very high, impacting pricing and affordability, particularly among low-resource countries where rabies is highly prevalent, such as in Africa. Producing these types of vaccines requires a significant amount of funding, creating high costs.
• Vaccine Hesitancy: Increasing vaccination rates hinges on addressing vaccine hesitancy and misinformation. Public education and engagement are required to remove barriers to vaccine acceptance.

These drivers and challenges significantly impact the rabies vaccine market by influencing innovation, access, and public health efforts. Rabies control can be improved, and vaccination coverage extended by addressing these elements.

List of Rabies Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies rabies vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the rabies vaccine companies profiled in this report include-

• Serum Institute of India
• Novartis
• Cadila Pharmaceuticals
• Merck
• Sanofi
• ADS Diagnostic
• GSK

Rabies Vaccine by Segment

The study includes a forecast for the global rabies vaccine market by product type, vaccination type, application, end use, and region.

Rabies Vaccine Market by Product Type [Analysis by Value from 2019 to 2031]:

• Baby Hamster Kidney
• Purified Chick Embryo Cell Rabies Vaccine
• Vero Cell Rabies Vaccine
• Others

Rabies Vaccine Market by Vaccination Type [Analysis by Value from 2019 to 2031]:

• Pre-Exposure Vaccination (PEV)
• Post-Exposure Prophylaxis (PEP)

Rabies Vaccine Market by Application [Analysis by Value from 2019 to 2031]:

• Animal
• Human

Rabies Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Rabies Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Rabies Vaccine Market

The rabies vaccine market is changing rapidly due to progress in vaccine technology, increased awareness, and differing global health priorities. These trends are evident in recent developments in the United States, China, Germany, India, and Japan, which demonstrate global efforts to curb and prevent rabies.

• USA: New safety-enhanced rabies vaccines with improved post-exposure prophylaxis regimens have been developed. Recent research has led to recombinant vaccines that are more effective and have fewer side effects.
• China: Rabies vaccination programs are being expanded in China, especially in rural areas where the disease is rampant. The government has also increased funding for vaccination campaigns and studies on more potent vaccines.
• Germany: Germany's focus has shifted toward combination vaccines offering protection against many diseases, including rabies. This approach aims to create a consolidated immunization program that will increase the number of immunized individuals.
• India: New intervention programs revolve around the wider distribution of anti-rabies vaccines among vulnerable communities. Access to vaccines will be improved by conducting campaigns in public health systems and partnering with organizations involved in immunization.
• Japan: In Japan, investments in advanced research on rabies vaccinations, including novel delivery mechanisms, have been made. These innovations aim to improve the efficacy of vaccines, particularly for travelers and pet owners who prioritize convenience.

Features of the Global Rabies Vaccine Market

Market Size Estimates: Rabies vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Rabies vaccine market size by various segments, such as by product type, vaccination type, application, end use, and region in terms of ($B).

Regional Analysis: Rabies vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, vaccination types, applications, end uses, and regions for the rabies vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the rabies vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the rabies vaccine market by product type (baby hamster kidney, purified chick embryo cell rabies vaccine, vero cell rabies vaccine, and others), vaccination type (pre-exposure vaccination (PEV) and post-exposure prophylaxis (PEP)), application (animal and human), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Rabies Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Rabies Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Rabies Vaccine Market by Product Type
  • 3.3.1: Baby Hamster Kidney
  • 3.3.2: Purified Chick Embryo Cell Rabies Vaccine
  • 3.3.3: Vero Cell Rabies Vaccine
  • 3.3.4: Others
• 3.4: Global Rabies Vaccine Market by Vaccination Type
  • 3.4.1: Pre-Exposure Vaccination (PEV)
  • 3.4.2: Post-Exposure Prophylaxis (PEP)
• 3.5: Global Rabies Vaccine Market by Application
  • 3.5.1: Animal
  • 3.5.2: Human
• 3.6: Global Rabies Vaccine Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Homecare
  • 3.6.3: Specialty Clinics
  • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Rabies Vaccine Market by Region
• 4.2: North American Rabies Vaccine Market
  • 4.2.1: North American Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.2.2: North American Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Rabies Vaccine Market
  • 4.3.1: European Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.3.2: European Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Rabies Vaccine Market
  • 4.4.1: APAC Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.4.2: APAC Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Rabies Vaccine Market
  • 4.5.1: ROW Market by Product Type: Baby Hamster Kidney, Purified Chick Embryo Cell Rabies Vaccine, Vero Cell Rabies Vaccine, and Others
  • 4.5.2: ROW Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Rabies Vaccine Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Rabies Vaccine Market by Vaccination Type
  • 6.1.3: Growth Opportunities for the Global Rabies Vaccine Market by Application
  • 6.1.4: Growth Opportunities for the Global Rabies Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Rabies Vaccine Market by Region
• 6.2: Emerging Trends in the Global Rabies Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Rabies Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Rabies Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Serum Institute of India
• 7.2: Novartis
• 7.3: Cadila Pharmaceuticals
• 7.4: Merck
• 7.5: Sanofi
• 7.6: ADS Diagnostic
• 7.7: GSK